Obesity is widely known for increasing the risk of diabetes and cardiovascular disease, but its damaging effects on the ...

The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, ...

Researchers show that pharmacological activation of hypoxia signaling improves metabolism, limits fat accumulation, and ...

In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy design ...

A “VERY talented” young student, 20, died after he contracted sepsis from “inadequate hospital hygiene”. Joshua ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda. has received approval from ...

Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 -- Positive Opinion from European ...

Bone remodeling is a dynamic and tightly regulated process that maintains skeletal integrity throughout life. Central to this process are osteoclasts, the ...